Dr. Sang-Hun Lee, director of the R&D center at Curexo Inc., a Korean medical robot company, is an expert in robotics who has been working in this field for more than 25 years. From 1996, he developed control and sensor technologies for industrial robots at Hyundai Heavy Industries, a Korean industrial robot company. And from 2009, he developed medical robots at the same company. Since 2017, he has been leading the development of orthopedic surgical robots and rehabilitation robots in Curexo. He earned a Ph.D. degree in mechanical engineering in 2006, M.S. in 1996, and B.S. in 1994, respectively, in Hanyang University, Korea.

PRESENTATION TITLE: Experiences of developing a gait training robot toward the aging society

“Walking ability is an important factor of the quality of life for the elderly people. In this lecture, a Korean gait training robot “Moring Walk” and robotic technologies toward the aging society will be introduced.”

Jaesoon Choi received B.S. degree in control and instrumentation engineering and M.S. and Ph.D. degree in biomedical engineering from Seoul National University. He had research training at the Department of Biomedical Engineering, Cleveland Clinic, U.S.A., from 1999 to 2000. Between 2003 and 2006, he worked as a Staff Researcher at Research Institute, National Cancer Center, Korea. From 2007 to 2012, he was with College of Medicine, Korea University as Research Professor. He is currently an Associate Professor at Dept. of Biomedical Engineering, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. His research interest includes surgery / intervention assist robot, medical simulation / visualization, bioprinting technologies and mechatronics applications in biomedicine.

Dr Amy Wilson is CEO of Clever.Care, a Swiss-based digital health start-up providing a coordination tool for caregivers of older people.
Amy’s experience spans both academia and industry, always with a focus on how enable better quality of life for people as they age.
In her previous role at the Global Centre for Modern Ageing (based in Australia), Amy worked across many industries to identify market opportunities and co-develop new innovations to meet the needs of the ageing demographic. These projects included autonomous vehicles, tech-enabled rehabilitation and assistive-care devices, and telemedicine, across many geographies, including Australia, Hong Kong and Israel.

Dr. So Ra Park is the chair & founder of the Regenerative Medicine Acceleration Foundation which is under the Advanced Regenerative Medicine Support Organization, designated by Ministry of Health & Welfare since March 2021.
The RMAF is a non-profit foundation, established in Feb.2021, aims for National Health Promotion through providing and expanding new medical opportunities under the national responsibility in accordance with the purpose of the “Act on The Safety and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals” (abbreviation is “Advanced Regeneration Bio Act.”)
As a support organization, RMAF dose various activities for accelerating technology developments and supporting policies developments on safety managements. In addition, she is actively engaged in advisory committees on healthcare and advanced regenerative medicine related field in South Korea. In recognition of her activities, she was awarded a Service Merit Medal in 2018.
She is also a professor of physiology at School of Medicine, Inha University since 1991. She got BA, MD, PhD in Physiology at Yeonsei University, South Korea.

PRESENTATION TITLE: Opportunities and Challenges in South Korea

“Korea shows a remarkable progress in regenerative medicine (RM) including the world’s first approved stem cell product. Its expertise and achievements are reinforced by the favorable government support with excellent regulatory environment and funding. Furthermore, R&D infrastructure is of a high stand in Korea for fundamental research and medical innovation in the field of RM as well. Also, the Advanced Regenerative Bio Act has been approved in April 2019 that will further accelerate commercial development of and patient access to RM.

By looking at the purpose and expected effects of the Advanced Regenerative Bio Act, the presentation will provide an overview of the Korean stem cell & regenerative medicine industry, the opportunities and challenges that exist, and how best to navigate the market towards accelerated commercialization of novel technologies.”

Shayesteh Fürst-Ladani is the CEO and founder of SFL. She leads the team at SFL and provides global strategic support for the development of healthcare products. Shayesteh is President of the not-for-profit Associations “Rare Disease Action Forum” (RDAF) as well as the “Medtech & Pharma Platform” (MPP). Shayesteh has longstanding experience in formulating global regulatory strategy for drugs, orphan drugs, drug & device combination products, borderline products, medical devices, in vitro diagnostics (IVDs) and advanced therapy medicinal products (ATMPs). She is a Special Coach for Regulatory Affairs at Innosuisse (the Swiss Innovation Agency). Shayesteh is a Lecturer in Regulatory Affairs at the IFAPP Academy, Kings College London and previously spent 7 years as an Adjunct Instructor for Regulatory Affairs at the George Washington University School of Medicines and Health Sciences. She is frequently invited as a speaker and/or chair in international conferences.

PRESENTATION TITLE: Cell and gene therapies at the forefront of innovation in Europe – challenges and opportunities

“Cell and gene therapies are at the forefront of innovation and offer new promising treatments for previously incurable diseases. An innovative ecosystem is crucial for promoting the development of these therapies and improving patient access. This presentation will provide an overview of the regulatory framework for cell and gene therapies in Switzerland and the EU, as well focus on current challenges and latest developments. Furthermore, current initiatives will be highlighted that aim to foster collaboration among stakeholders in Europe.”

Maximilien is a Scientific Executive with experience in start-up establishment, management and fund raising. He joined Cellestia as co-founder in 2015 and COO in 2017, with 20+ years of experience in the pharma/life sciences industry. Before joining Cellestia, Maximilien served as the Managing Director for AdipoGen Life Sciences. In addition, Maximilien served for 10 years as Associate Director at Debiopharm International SA, where he was managing the Early Projects team. Maximilien holds a PhD from the Swiss Institute of Experimental Cancer Research, and an executive MBA from HEC Lausanne. He spent three years as postdoctoral researcher in the Department of Molecular Oncology at Genentech, Inc., South San Francisco, USA.

Orlando D. Schärer received a Diplom (MSc) from ETH Zürich (Switzerland), a PhD from Harvard University (USA) and did postdoctoral studies at Erasmus University (Netherlands). He held faculty positions at the University of Zürich, Switzerland (1999-2005) and Stony Brook University, NY, USA (2005-2016) before taking up his current positions in Ulsan, Korea, as Associate Director at the Center for Genomic Integrity of the Institute for Basic Science and Distinguished Professor of Life Sciences at UNIST. His research combines chemical and biological approaches to study DNA damage, DNA repair and DNA damage signaling pathways and their relationship to carcinogenesis and antitumor therapy.

Christian focuses on ensuring the success of Novartis’ digital partnerships and activities across the region, supporting all country teams in implementing solutions that deliver impact at scale. As Head of Biome Singapore, his role involves designing the strategy and operational activities to deliver on improved patient outcomes, as well as a model for sourcing, evaluating and partnering with digital health companies at the Biome Singapore Digital Innovation Lab site.

Prior to joining Novartis, Christian was part of the Business Model Factory for Deloitte Tohmatsu Venture Support in Japan, providing open innovation consulting for large corporations and government agencies. He was also an innovation lead for Deloitte Southeast Asia and OCBC Bank in Singapore (Fintech & Innovation Group).

Christian holds a Bachelor of Arts in Sociology and Media & Communications from the University of Melbourne. He is currently pursuing a Master of Science in Information Studies from Nanyang Technological University.

PRESENTATION TITLE: Open innovation at Novartis – A tripartite innovation model of pharma, healthcare systems and health-techs.

“What does open innovation mean to Novartis in designing and delivering digital health solutions?
How have we responded to this need through the Novartis Biome Digital Innovation Lab?
Where have we successfully delivered digital health solutions?
How can healthcare systems and health-techs partner with Novartis?”

Célia Oculi is a French national with broad international experience in several fields including strategy, healthcare transformation and partnerships.
Célia joined Roche in 2014, and since three years, she leads the Center of excellence for Personalised Healthcare of Roche Belgium and Luxembourg. In this role, she defines the strategy for the personalized healthcare portfolio and drives transformative partnerships with clinicians, medical societies, health authorities and untraditional players to shape a sustainable and data driven healthcare ecosystem.
Before joining Roche, she served as senior consultant at Ernst&Young where she led the investment review for public life science investments in France and developed strong expertise in innovation acceleration and business modelling.

PRESENTATION TITLE: Belgian Journey toward Data Driven Ecosystem

“Covid pandemic has reinforced Data driven ecosystem as key enabler of efficient and sustainable health system. The journey toward data driven ecosystem in Belgium has started years ago and today Roche is supporting key public private initiatives to accelerate the transformation of local health system and design the future of digital health.”

Edward Choi is an assistant professor of the Graduate School of AI at KAIST. He received his PhD in computer science at Georgia Tech in 2018, where he studied interpretable deep learning models for healthcare analytics under the supervision of professor Jimeng Sun. Prior to joining KAIST in 2020, Edward was a software engineer at Google Health Research, where he focused on developing deep learning models for processing electronic health records. His current research interests include machine learning, healthcare and natural language processing.

Mario Garcia-Lee is the CEO of Lighting Up Ventures, in charge of Strategy and Implementation. He is an educator, scientist, and entrepreneur who specializes in the intersection between innovation and commercialization, help regions accelerate economic growth and job creation through innovation-driven entrepreneurship. Gaining an interest in how advanced technologies could improve everyday life, Mario obtained an MBA from Yonsei School of Business and was sponsored by South Korea’s Ministry of Strategy and Finance to assess support systems for innovation-driven enterprises as part of MIT’s Regional Entrepreneurship Acceleration Program. He has taught courses and workshops in technology entrepreneurship at Yonsei University, Korea Advanced Institute of Science and Technology, and various other institutions supporting entrepreneurs.